Andere talen Odyssey Health, Inc.

Aandelen

ODYY

US67612C1027

Vertraagde tijd OTC Markets Andere beurzen 15:48:06 14-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,0415 ^USD	-17,00%		+38,80%	-58,50%

22/03	Odyssey Health, Inc. Rapporteert winstresultaten voor het tweede kwartaal en de zes maanden eindigend op 31 januari 2024	CI
2023	Oragenics, Inc. (NYSEAM:OGEN) heeft de overname afgerond van Activa met betrekking tot neurologische geneesmiddelentherapieën en technologieën van Odyssey Health, Inc.	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	22/03
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	28/12
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	15/12
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	30-10-23
Odyssey Health, Inc. Announces the Resignation of John Gandolfo as Director	06-10-23
Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate	06-10-23
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	05-10-23
Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS	23-08-23
AM Best Upgrades Credit Ratings of Odyssey Group Holdings, Inc.'s Members	07-07-23
Odyssey Health, Inc. executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.	28-06-23
Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	14-06-23
ODYSSEY HEALTH, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	04-04-23
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment	30-03-23
ODYSSEY HEALTH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	17-03-23
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	17-03-23
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	17-03-23
Odyssey Health, Inc. Forms Community-Based Partnership with David R. Metcalf Foundation for Military Concussion Research	07-02-23
ODYSSEY HEALTH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	13-01-23
Odyssey Health, Inc. Appoints Jeffrey Conroy as Director	13-01-23
Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote	12-01-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Odyssey Health, Inc.

Aandelen

ODYY

US67612C1027

Andere talen

Filters